Literature DB >> 7583915

Reversal of immunosuppression of lymphocyte proliferation caused by sera from persons with AIDS.

R H Tomar1, P John, P Hinds.   

Abstract

Sera from persons with AIDS contain inhibitors of lymphocyte proliferation. Inhibitory activity can be detected before the development of AIDS in humans. There appear to be at least three distinct suppressive moieties, one of which is prostaglandin E2. We and others had previously shown that serum samples from subjects with AIDS contained antibody to the cell line HUT 102B2. We attempted to remove this antibody and to determine if that action would also remove the inhibitory activity present in human immunodeficiency virus-positive sera. We incubated sera from subjects with AIDS with HUT 102B2 cells and tested the resultant supernatants for inhibition of cell proliferation. We found that this procedure significantly reversed inhibition by serum. Other cells and cell lines were similarly tested, but only HUT 102B2 cells absorbed the inhibitory product(s). However, we determined that secretory material from another cell line, MLA 144, also reversed inhibition. The physical characteristics of the supernatant were investigated. Thus, two procedures and likely separate products, possibly cytokines, reverse immunosuppression by sera from persons with AIDS.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7583915      PMCID: PMC170170          DOI: 10.1128/cdli.2.4.408-411.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  18 in total

1.  HIV-1 infection abolishes CD4 biosynthesis but not CD4 mRNA.

Authors:  M A Yuille; M Hugunin; P John; L Peer; L V Sacks; B J Poiesz; R H Tomar; A E Silverstone
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1988

2.  Antibodies to human T-cell lymphotropic virus-I membrane antigens and inverted T4/T8 ratios in hemophiliacs.

Authors:  B E Kloster; R H Tomar; J A Stockman; H V Lamberson; S A Merl; P A John; D M Groth; B J Poiesz
Journal:  Am J Clin Pathol       Date:  1985-04       Impact factor: 2.493

3.  Sera from patients with the acquired immunodeficiency syndrome inhibit production of interleukin-2 by normal lymphocytes.

Authors:  J P Siegel; J Y Djeu; N I Stocks; H Masur; E P Gelmann; G V Quinnan
Journal:  J Clin Invest       Date:  1985-06       Impact factor: 14.808

4.  Inhibition of interleukin-2-induced T-cell proliferation by sera from patients with the acquired immune deficiency syndrome.

Authors:  R P Donnelly; K Y Tsang; G M Galbraith; J I Wallace
Journal:  J Clin Immunol       Date:  1986-01       Impact factor: 8.317

5.  Serum factors in the progression of human immunodeficiency virus type 1 infection to AIDS.

Authors:  R H Tomar; A K Hennig; R P Oates; M A Yuille; P A John
Journal:  J Clin Lab Anal       Date:  1990       Impact factor: 2.352

6.  Inhibition of interleukin 2 production and expression of the interleukin 2 receptor by plasma from acquired immune deficiency syndrome patients.

Authors:  J L Farmer; A A Gottlieb; T Nishihara
Journal:  Clin Immunol Immunopathol       Date:  1986-02

7.  Serum inhibitors precede the development of SAIDS.

Authors:  R H Tomar; P Carey; P Hinds; K Schultz
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-09

8.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  Antibodies to cell membrane antigens associated with human T-cell leukemia virus in patients with AIDS.

Authors:  M Essex; M F McLane; T H Lee; L Falk; C W Howe; J I Mullins; C Cabradilla; D P Francis
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro.

Authors:  M Clerici; D R Lucey; J A Berzofsky; L A Pinto; T A Wynn; S P Blatt; M J Dolan; C W Hendrix; S F Wolf; G M Shearer
Journal:  Science       Date:  1993-12-10       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.